A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: A gynecologic oncology group study

Gynecologic Oncology

Volumn 87, Issue 3, 2002, Pages 247-251

  Miller, David Scott ^a   Blessing, John A ^b   Lentz, Samuel S ^c   Waggoner, Steven E ^d   Mackey, Denise ^e  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e Gynecologic Oncology Group   (United States)

Author keywords

Camptothecin; Topoisomerase 1 inhibition; Topotecan

Indexed keywords

TOPOTECAN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BLEEDING; BRADYCARDIA; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG RESPONSE; EDEMA; ENDOMETRIUM CARCINOMA; FATALITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL DISEASE; HORMONAL THERAPY; HUMAN; INFECTION; LEUKOPENIA; LUNG INJURY; LYMPHOCYTOPENIA; METABOLIC DISORDER; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; THROMBOCYTOPENIA; TOXICITY TESTING; TREATMENT FAILURE; TREATMENT OUTCOME; VOMITING;

EID: 0036926109     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2002.6804     Document Type: Article

References (35)

1. Coleman RL, Miller DS. Topotecan in the treatment of gynecologic cancer. Semin Oncol 1997;24(6 Suppl 20):S55-63.
2. Horton J, Begg C, Arseneau J, et al. Comparison of adriamycin with cyclophosphamide in patients with advanced endometrial cancer. Cancer Treatment Rep 1978;62:159.
3. Thigpen T, Buchsbaum H, Mangan C, et al. Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma: A gynecologic oncology group study. Cancer Treatment Rep 1979;63:21-27.
4. Thigpen T, Blessing J, Lagasse L, et al. Phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: AGynecologic Oncology Group study. Am J Clin Oncol 1984;3:253-56.
5. Thigpen T, Blessing, Homesley H, et al. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: A gynecologic Oncology Group study. Gynecol Oncol 1989; 33:68-70.
6. Sutton GP, Blessing JA, Homesley HD, McGuire WP, Adcock L. Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group study. Cancer 1994;73(5):1453-55.
7. Sutton GP, Blessing JA, DeMars LR, Moore D, Burke TW, Grendys EC. A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium. Gynecol Oncol 1996;63:25-27.
8. Ball HG, Blessing JA, Lentz SS, Mutch DG. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: A Gynecologic Oncology Group study. Gynecol Oncol 1996;62: 278-81.
9. Houghton PJ, Cheshire PJ, Myers L, Stewart CF, Synold TW, Houghton JA. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol 1992;31:229-39.
10. Armstrong D, O'Reilly S. Clinical guidelines for managing topotecan related hematologic toxicity. Oncologist 1998;4-10.
11. Blessing JA. Design, analysis and interpretation of chemotherapy trials in gynecologic cancer. In: Deppe G, editor. Chemotherapy of Gynecologic Cancer. New York: Liss, 1990.
12. Thigpen JT, Brady MF, Alvarez RD, Adelson MD, Homesley HD, Manetta A, Soper JT, Given FT. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: A dose-response study by the Gynecologic Oncology Group. J Clin Oncol 1999;17:1736-44.
13. Slayton R, Blessing J, Delgado G. Phase II trial of etoposide in the management of advanced or recurrent endometrial carcinoma. Cancer Treatment Rep 1982;66:1669-71.
14. Stehman F, Blessing J, Delgado G, et al. Phase II evaluation of dianhy-drogalactitol in the treatment of advanced endometrial adenocarcinoma: A Gynecologic Oncology Group study. Cancer Treatment Rep 1983;67:737.
15. Slavik M, Petty W, Blessing J, et al. Phase II clinical study of tamoxifen in advanced endometrial adenocarcinoma: A Gynecologic Oncology Group study. Cancer Treatment Rep 1984;68:809-11.
16. Homesley H, Blessing J, Conroy J, et al. ICRF-159 (Razoxane) in patients with advanced adenocarcinoma of the endometrium: A Gynecologic Oncology Group study. Am J Clin Oncol 1986;9:15-17.
17. Thigpen T, Blessing J, Homesley H, et al. Phase II trial of piperazinedione in the treatment of advanced or recurrent endometrial carcinoma. Am J Clin Oncol 1986;9:21-23.
18. Muss H, Bundy B, DiSaia P, et al. Mitoxantrone for carcinoma of the endometrium: A phase II trial of the Gynecologic Oncology Group. Cancer Treat Rep 1987;71:217-18.
19. Slayton R, Blessing J, DiSaia P, Phillips G. A phase II clinical trial of diaziquone in the treatment of patients with recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Am J Clin Oncol 1988;11:612-13.
20. Asbury R, Blessing J, McGuire W, et al. Aminothiadiazole (NSC 4728) in patients with advanced carcinoma of the endometrium: A phase II study of the Gynecologic Oncology Group. Am J Clin Oncol 1990;13:39-41.
21. Muss H, Blessing J, Hatch K, et al. Methotrexate in advanced endometrial carcinoma: A phase II trial of the Gynecologic Oncology Group. Am J Clin Oncol 1990;13:61-63.
22. Muss H, Budy B, Adcock L. Teniposide (VM-16) in patients with advanced endometrial carcinoma: A phase II trial of the Gynecologic Oncology Group. Am J Clin Oncol 1991;14:36-37.
23. Broun GO, Blessing JA, Eddy GL, Adelson MD. A phase II trial of vincristine in advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group Study. Am J Clin Oncol 1993;16:18-21.
24. Muss HB, Blessing JA, DuBeshter B. Echinomycin in recurrent and metastatic endometrial carcinoma: A phase II trial of the Gynecologic Oncology Group. Am J Clin Oncol 1993;16(6):492-93.
25. Rose PG, Blessing JA, Lewandowski GS, Creasman WT, Webster KD. A phase II trial of prolonged oral etoposide (VP-16) as a second-line therapy for advanced and recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 1996;63:101-04.
26. Asbury R, Blessing JA, Reid GC, McGuire WP. A phase II trial of amonafide in patients with endometrial cancer: A Gynecologic Oncology Group Study. Am J Clin Oncol 1998;21:406-07.
27. Moore DH, Blessing JA, Dunton C, Buller RE, Reid GC. Dactinomycin in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group. Gynecol Oncol 1999;75:473-75.
28. Rose PG, Brunetto VL, VanLe L, Bell J, Walker JL, Lee RB. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2000;78: 212-16.
29. Thigpen T, Blessing J, Ball H, et al. Hexamethylmelamine as first-line chemotherapy in the treatment of advanced or recurrent carcinoma of the endometrium: A phase II trial of the Gynecologic Oncology Group. Gynecol Oncol 1988;31:435-38.
30. Thigpen JT, Blessing JA, DiSaia PJ, Yordan E, Carson LF, Evers C. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 1994;12:1408-14.
31. Barrett RJ, Blessing JA, Homesley HD, Twiggs L, Webster KD. Circadian-timed combination doxorubicin-cisplatin chemotherapy for advanced endometrial carcinoma: A phase II study of the Gynecologic Oncology Group. Am J Clin Oncol 1993;16:494-96.
32. Fleming GF, Brunetto VL, Bentley R, Rader J, Clarke-Pearson D, Sorosky J, Eaton L, Gallion H, Gibbons WE. Randomized trial of doxorubicin plus cisplatin versus doxorubicin plus paclitaxel plus granulocyte colony-stimulating factor (G-CSF) in patients with advanced or recurrent endometrial cancer: A report on Gynecologic Oncology Group protocol #163. Proc ASCO 2000; No. 102404 (abstract).
33. Markman M, Blessing JA, Alvarez RD, Hanjani P, Waggoner S, Hall K. Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study. Gynecol Oncol 2000;77:112-15.
34. Hochster H, Wadler S, Runowicz C, Liebes L, Cohen H, Wallach R, Sorich J, Taubes B, Speyer J. Activity and pharmacodynamics of 21-day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group. J Clin Oncol 1999;17:2553-61.
35. Hall JB, Higgins RV, Naumann RW, Groblewski M. Phase II study of topotecan and cisplatinum for stages III and IV or recurrent endometrial cancer. Proc ASCO 2000; No. 1622 (abstract).